Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Vesugen
Also known as: Lys-Glu-Asp, KED
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator program, designed as a vascular system bioregulator. It is proposed to support cardiovascular health by normalizing endothelial function and improving vascular tone. Evidence is limited to in vitro studies and small Russian observational trials, primarily in elderly populations.
Risk Level
Low RiskDifficulty
Intermediate| Molecular Formula | C15H26N4O8 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Proposed to regulate gene expression in vascular endothelial cells, improving endothelial function and reducing vascular inflammation. In vitro studies suggest promotion of endothelial cell proliferation and modulation of genes involved in angiogenesis and vascular remodeling.
Dosing Research
Oral capsules: 10 mg 1-2 times daily for 15-30 days. May be combined with other cardiovascular-targeted bioregulators. Repeat courses every 3-6 months. No injectable formulation commonly used.
Side Effects & Risks
No significant adverse effects reported. Theoretical concern about promoting angiogenesis in individuals with occult malignancies. Overall considered low-risk due to rapid peptide degradation, but the evidence base is insufficient for confident safety assessment.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.